AgeX Therapeutics, Inc. announced In connection with the termination of the agreement pursuant to which Juvenescence has provided the services of Chief Operating Officer, Nafees Malik, as set forth Item 1.02 of this Report, Dr. Malik?s engagement as Chief Operating Officer of AgeX and subsidiary Reverse Bioengineering, Inc. will terminate on December 27, 2023. On November 27, 2023, Juvenescence Limited (?Juvenescence?) notified AgeX that Juvenescence is terminating a March 29, 20219 the agreement that incorporated arrangements in effect since October 18, 2018 pursuant to which Juvenescence has provided AgeX with the services of Juvenescence?s employee Nafees Malik who served as Chief Operating Officer of AgeX and subsidiary Reverse Bioengineering, Inc. The agreement will terminate on December 31, 2023 when Dr. Mailk?s employment by Juvenescence will come to an end. Under the agreement for Dr. Malik?s services the company has been paying Juvenescence 85% of Dr. Malik?s base salary from Juvenescence and the company has been entitled to receive an allocation of 85% of Dr. Malik?s time as an employee of Juvenescence.